Fixed Ratio Lymphocyte Compositions for Tumor Evasion Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current adoptive lymphocytic therapies, such as CAR-T cell therapies, face limitations including tumor evasion due to antigen down-regulation or mutation, restricted antigen targeting, significant inflammatory toxicities, limited persistence, and variability in T-cell subset ratios, which hampers their effectiveness in treating hematological and solid tumors.
Innovation Solution
Development of isolated cell compositions comprising a standardized, non-naturally occurring fixed ratio of multiple ex vivo activated non-engineered lymphocytic cell subsets, including CD4+ T-cells, CD8+ T-cells, CD3+/CD56+ NKT-cells, and γδ T-cells, to enhance immune response comprehensiveness and durability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If CAR-T cell therapy is used to target a specific antigen, then potent anti-tumor effects are achieved, but tumors can evade by down-regulating or mutating the target antigen
Solution Approach 1:
The patent employs multiple different CAR-T cell products targeting different antigens (CD19, CD22, CD70, etc.) simultaneously or sequentially. This multi-target approach ensures that if a tumor evades one CAR-T product by down-regulating or mutating a specific antigen, other CAR-T products targeting different antigens can still effectively attack the tumor, thereby achieving universal coverage and preventing evasion.
2Object-affected harmful factors
If non-engineered T-cell therapy is used to avoid inflammatory toxicities, then patient safety is improved, but T-cell persistence and durable immunity are limited
Solution Approach 1:
The patent modifies key parameters of non-engineered T-cells through ex vivo manipulation, including activation state, cytokine exposure, and expansion conditions. These parameter changes enhance the T-cells' persistence capabilities and durability while maintaining their non-engineered status, thus avoiding inflammatory toxicities associated with CAR-T therapy while achieving durable immunity.
3Productivity
If ex vivo expansion of T-cells is used to achieve robust T-cell response, then clonal expansion is enhanced, but variability in T-cell subset ratios reduces treatment consistency
Solution Approach 1:
The patent implements quality control measures with defined acceptance criteria for T-cell subset ratios (e.g., CD4+ T-cells: 10-50%, CD8+ T-cells: 30-70%, NK cells: 5-20%). These feedback mechanisms ensure that only T-cell products meeting the specified ratio consistency standards are approved for administration, thereby maintaining treatment consistency despite ex vivo expansion variability.
4Device complexity
If limited antigen targeting is used in CAR-T therapy, then manufacturing complexity is reduced, but the number of treatable tumor types is restricted
Solution Approach 1:
The patent develops a platform approach with multiple CAR-T products targeting different antigens (CD19 for B-cell malignancies, CD22 for B-cell malignancies, CD70 for renal cell carcinoma, etc.). This multi-functional platform can be adapted to treat various tumor types by selecting appropriate antigen targets, thereby achieving versatility without overwhelming manufacturing complexity through standardized production processes.
Data Source
AI summary
The present invention provides isolated cell compositions for the treatment of cancer, including hematological and solid tumors, comprising a selected, fixed ratio of multiple ex vivo activated lymphocytic cell subsets, including specific immune effector cells directed to specific tumor associated antigens (TAAs), viral associated tumor antigens (VATA), glycolipids, or a combination thereof. By selecting specific fixed ratios of different lymphocytic cell subsets, an immune response which is comprehensive and broad pin biological and immune effector function is provided, enhancing the ability of the administered cells to mount an effective and robust immune response.